Work

Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.6_suppl.tps588

Authors: Bradley Alexander McGregor, Lucia Kwak, Charlene Mantia, Arvind Ravi, Jacob E Berchuck, Praful Ravi, Wenxin Xu, Martha Tuff, Joaquim Bellmunt, Xin Gao, Rajitha Sunkara, Guru P. Sonpavde

Institutions: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Harvard University, Massachusetts General Hospital, Beverly Hospital

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4212879205

Cites:

Cited by: 7

Related to: 10